ABSTRACT
This chapter describes trade name, classification, approved Indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, and clinically significant drug interactions of Trazodone. Safety and efficacy of trazodone pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. Trazodone is excreted in breast milk. The potential for suicide among patients receiving trazodone pharmacotherapy for the symptomatic management of depression remains until significant remission occurs. Trazodone pharmacotherapy has been associated with the development of severe blood disorders. Trazodone pharmacotherapy commonly has been associated with dizziness, drowsiness, headache, dry mouth, and nausea or vomiting. Signs and symptoms of trazodone overdosage are similar to the ADRs associated with trazodone pharmacotherapy. Trazodone overdosage requires emergency symptomatic medical support of body systems with attention to trazodone elimination.
